Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptamer Group Regulatory News (APTA)

Share Price Information for Aptamer Group (APTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.85
Bid: 0.80
Ask: 0.90
Change: 0.00 (0.00%)
Spread: 0.10 (12.50%)
Open: 0.85
High: 0.85
Low: 0.85
Prev. Close: 0.85
APTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing Interim Review

29 Feb 2024 07:00

RNS Number : 8687E
Aptamer Group PLC
29 February 2024
 

29 February 2024

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Block Listing Interim Review

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:

 

 

Name of Company

Aptamer Group plc

Name of Scheme

The Aptamer Group EMI Share Option Scheme

Period of Return (from/to)

25 August 2023 to 24 February 2024

Number and class of securities not issued at the start of the period under the scheme

1,666,477 Ordinary Shares

Number of securities issued under the scheme during the period

0

Balance under the scheme of securities not yet issued at the end of the period

1,666,477 Ordinary Shares

Number and class of securities originally admitted and the date of admission

2,063,200 Ordinary Shares on 25 February 2022

Name of contact and telephone number

Andrew Rapson +44 (0) 1904 217 404

 

 

 

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Steve Hull

+44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser  

Andrew Emmott / Mark Brady / Adam Dawes

+44 (0) 20 3368 3550

Turner Pope Investments (TPI) Limited - Broker  

James Pope / Andrew Thacker

+44 (0) 20 3657 0050

 

 

About Aptamer Group plc

 

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRBVLLLZLLXBBZ
12
Date   Source Headline
26th Jul 202310:57 amRNSResponse to Speculation, Strategic Review, Update
7th Jul 20237:00 amRNSContract Wins
4th Jul 20237:00 amRNSTrading Update
14th Jun 202312:16 pmRNSResponse to Share Price Movement
14th Jun 20237:00 amRNSAptamer & Neuro-Bio to develop Alzheimer’s test
10th May 20237:00 amRNSAptamer Group: Directorate Change
5th May 20237:00 amRNSTrading Update
5th Apr 202311:25 amRNSTotal Voting Rights
20th Mar 20237:00 amRNSOptimer-Fc launched for immunohistochemistry
17th Mar 20237:00 amRNSInvestor Webinar
14th Mar 20237:00 amRNSInterim Results
1st Mar 20237:00 amRNSNotice of Interim Results
28th Feb 20235:45 pmRNSBlock listing Interim Review
13th Feb 20237:00 amRNSAppointment of Chief Financial Officer
1st Feb 20237:00 amRNSTotal Voting Rights
30th Jan 20237:00 amRNSAptamer Group project with consumer goods company
25th Jan 202312:09 pmRNSIssue of Equity and Total Voting Rights
24th Jan 20237:00 amRNSAptamer Group signs two substantial new contracts
16th Jan 20237:00 amRNSIssue of Equity and Total Voting Rights
9th Jan 20237:00 amRNSIssue of shares
3rd Jan 20237:00 amRNSHalf Year Trading Update
8th Dec 20227:00 amRNSInvestor Webinar
5th Dec 20227:00 amRNSInvestor Webinar
1st Dec 20225:07 pmRNSResults of 2022 Annual General Meeting
1st Dec 20227:00 amRNSAGM Statement
25th Nov 20227:00 amRNSAptamer Group to officially open new facilities
1st Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
18th Oct 20227:00 amRNSFull year results 2022
13th Oct 20227:00 amRNSNotice of Full Year Results
25th Aug 202212:35 pmRNSBlock Admission Six Monthly Return
22nd Aug 20227:00 amRNSFull Year Trading Update
13th Jun 20227:00 amRNSBoard and Management Change
23rd May 20227:00 amRNSAptamer Group and PinotBio extend collaboration
3rd May 20227:00 amRNSTotal Voting Rights
31st Mar 20227:00 amRNSInterim Results
28th Mar 20227:01 amRNSWastewater monitoring system installed in UK
3rd Mar 20227:43 amRNSTotal Voting Rights
24th Feb 20222:29 pmRNSCORRECTION: Block Listing Application
24th Feb 20227:01 amRNSBlock Admission Application
24th Feb 20227:00 amRNSHalf Year Trading Update and Notice of Results
17th Jan 20227:00 amRNSOPTIMER BINDER SHOWN TO DETECT OMICRON VARIANT
24th Dec 202110:06 amRNSHolding(s) in Company
23rd Dec 20218:55 amRNSHolding(s) in Company
22nd Dec 20218:00 amRNSAdmission to trading on AIM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.